机构：[1]Department of Breast Cancer Center, The Fourth Affi liated Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of China[2]Department of Orthopedics, The Fourth Affi liated Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of China
Selective estrogen receptor modulators (SERMs) are synthetic molecules which bind to estrogen receptors (ER) and can modulate their transcriptional capabilities in different ways in diverse estrogen target tissues. Unfortunately, the use of resistant therapy is associated with acquired resistance. Several molecular mechanisms have been proposed to be responsible for endocrine resistance in breast cancer, including MIR-451, FGF and FGFR, ADAM12, fibronectin and other soluble stromal factors, PELP1-KDM1, HER2, NOTCH, delta Ef1, mTOR, AKT/mTOR, Pi3K/AKT, Pi3K/AKT/mTOR, NF kappa B, LMTK3, IGF1R, cyclin E2, IRF1, Tab2, and SRC-1. Further research is needed to know more about endocrine resistance.
第一作者机构：[1]Department of Breast Cancer Center, The Fourth Affi liated Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of China
共同第一作者：
通讯作者：
通讯机构：[1]Department of Breast Cancer Center, The Fourth Affi liated Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of China[*1]Department of Breast Cancer Center, The Fourth Affi liated Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of China
推荐引用方式(GB/T 7714)：
Zheng L. H.,Zhao Y. H.,Feng H. L.,et al.Endocrine resistance in breast cancer[J].CLIMACTERIC.2014,17(5):522-528.doi:10.3109/13697137.2013.864268.
APA：
Zheng, L. H.,Zhao, Y. H.,Feng, H. L.&Liu, Y. J..(2014).Endocrine resistance in breast cancer.CLIMACTERIC,17,(5)
MLA：
Zheng, L. H.,et al."Endocrine resistance in breast cancer".CLIMACTERIC 17..5(2014):522-528
